ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ZVRA Zevra Therapeutics Inc

4.96
-0.07 (-1.39%)
最終更新日: 00:00:08
15分遅延
名称 銘柄コード 市場 種別
Zevra Therapeutics Inc ZVRA NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.07 -1.39% 4.96 00:00:08
始値 安値 高値 終値 前日終値
4.95 4.89 5.05 5.03
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/1005:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/0920:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
2024/5/0820:54EDGAR2Form 8-K - Current report
2024/5/0820:00GLOBEZevra Therapeutics Reports First Quarter 2024 Financial..
2024/5/0120:30GLOBEZevra Therapeutics to Report First Quarter 2024 Results on..
2024/4/2920:30GLOBEZevra Therapeutics’ President and Chief Executive Officer..
2024/4/1606:01GLOBEZevra Therapeutics Presents New Data on the Long-Term Safety..
2024/4/1020:30GLOBEZevra Therapeutics Refinances Existing Debt with up to $100M..
2024/3/2905:32GLOBEZevra Therapeutics Reports Fourth Quarter and Full Year 2023..
2024/3/2820:42IHMARKETNEWSUS Stock Futures Stable in Pre-Market On Path for..
2024/3/2705:30GLOBEZevra Therapeutics Announces Top-Line Data from the Phase 2..
2024/3/2605:30GLOBEZevra Therapeutics to Present at the 23rd Annual Needham..
2024/3/1820:30GLOBEZevra Therapeutics to Report 2023 Fourth Quarter and Full..
2024/3/0521:34EDGAR2Form 8-K - Current report
2024/3/0422:24EDGAR2Form 8-K - Current report
2024/3/0421:30GLOBEZevra Therapeutics Provides FDA Update on the PDUFA Action..
2024/2/2821:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
2024/2/1506:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2024/2/0621:30GLOBEZevra Therapeutics to Present at the Oppenheimer 34th Annual..
2024/2/0311:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0310:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0221:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/2321:37EDGAR2Form 8-K - Current report
2024/1/2321:30GLOBEZevra Therapeutics Appoints Experienced Biopharma Executive..
2024/1/1206:50DJNXoma to Make $1 Million Milestone Payment to LadRx After FDA..
2024/1/0822:03EDGAR2Form 8-K - Current report
2024/1/0821:30GLOBEZevra Therapeutics Receives FDA Acceptance of Resubmission..
2024/1/0422:55GLOBEZevra Therapeutics Appoints Global Medical Leader, Adrian..
2023/12/2722:24DJNZevra Therapeutics Refiles Arimoclomol Application With FDA
2023/12/2721:48EDGAR2Form 8-K - Current report
2023/12/2721:30GLOBEZevra Therapeutics Announces Resubmission of Arimoclomol New..
2023/11/2021:36EDGAR2Form 8-K - Current report
2023/11/2021:30GLOBEZevra Therapeutics Completes Acquisition of Acer..
2023/11/0807:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0721:25EDGAR2Form 8-K - Current report
2023/11/0721:00GLOBEZevra Therapeutics Reports Corporate Updates and Third..
2023/10/3120:30GLOBEZevra Therapeutics to Report Third Quarter 2023 Results on..
2023/10/3105:42EDGAR2Form 425 - Prospectuses and communications, business..
2023/10/3021:25EDGAR2Form 8-K - Current report
2023/10/1920:30GLOBEZevra Therapeutics Celebrates and Supports Global..
2023/10/1205:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1113:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/10/1109:20EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/10/1106:12EDGAR2Form 8-K - Current report
2023/10/1106:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

最近閲覧した銘柄

Delayed Upgrade Clock